Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Drops By 92.5%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 74,900 shares, a decrease of 92.5% from the January 31st total of 993,200 shares. Approximately 3.7% of the shares of the company are short sold. Based on an average daily volume of 397,700 shares, the days-to-cover ratio is currently 0.2 days.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Aptose Biosciences in a report on Wednesday, February 12th. StockNews.com began coverage on shares of Aptose Biosciences in a report on Tuesday. They set a “hold” rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Bleichroeder LP acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned approximately 4.15% of Aptose Biosciences as of its most recent SEC filing. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

Aptose Biosciences Trading Down 10.7 %

Shares of APTO opened at $3.25 on Friday. The firm has a market cap of $6.96 million, a P/E ratio of -1.09 and a beta of 0.88. Aptose Biosciences has a 12 month low of $3.11 and a 12 month high of $58.18. The stock’s 50 day moving average is $6.02 and its two-hundred day moving average is $8.91.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.